OVID vs. OCGN, INBX, CMPX, FULC, RAPT, CYRX, GLUE, PRTC, SLDB, and ADCT
Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Ocugen (OCGN), Inhibrx Biosciences (INBX), Compass Therapeutics (CMPX), Fulcrum Therapeutics (FULC), Rapt Therapeutics (RAPT), CryoPort (CYRX), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Solid Biosciences (SLDB), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.
Ovid Therapeutics vs. Its Competitors
Ovid Therapeutics (NASDAQ:OVID) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Ovid Therapeutics has a net margin of -574.44% compared to Ocugen's net margin of -1,197.71%. Ovid Therapeutics' return on equity of -58.87% beat Ocugen's return on equity.
In the previous week, Ovid Therapeutics had 1 more articles in the media than Ocugen. MarketBeat recorded 3 mentions for Ovid Therapeutics and 2 mentions for Ocugen. Ocugen's average media sentiment score of 0.91 beat Ovid Therapeutics' score of 0.50 indicating that Ocugen is being referred to more favorably in the news media.
Ovid Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, indicating that its stock price is 320% more volatile than the S&P 500.
72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Ovid Therapeutics has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ovid Therapeutics presently has a consensus target price of $3.70, suggesting a potential upside of 135.67%. Ocugen has a consensus target price of $7.00, suggesting a potential upside of 334.78%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than Ovid Therapeutics.
Summary
Ovid Therapeutics beats Ocugen on 12 of the 17 factors compared between the two stocks.
Get Ovid Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ovid Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OVID) was last updated on 10/16/2025 by MarketBeat.com Staff